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Abstract   
 
Background: Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of 
chronic liver disease worldwide. It can progress to cirrhosis and hepatocellular 
carcinoma. There are currently no recommended pharmacologic therapies solely for the 
treatment of NAFLD; only weight loss and lifestyle modifications are widely agreed 
upon recommendations. The clinical trials reviewed here demonstrate evidence that 
synbiotics can be a successful form of treatment of NAFLD in addition to weight loss and 
lifestyle modification.   
 
Methods: An exhaustive search of the available medical literature was performed using 
MEDLINE-Ovid, Web of Science, and CINAHL. Search terms included “Non-alcoholic 
fatty liver disease” and “synbiotics.” Eligible studies were assessed using the GRADE 
criteria. 
 
Results: Three articles met the eligibility criteria. All 3 were randomized controlled 
trials, 2 of which were double-blind and were written by some of the same authors but 
were done 3 years apart using completely separate data. The results were consistent in 
that various elements of nonalcoholic fatty liver disease (NAFLD) significantly improved 
in the treatment groups compared to the control groups of all 3 studies. The quality of the 
outcomes is moderate to high, with a few limitations. Further studies done with the same 
synbiotic supplement and same duration of time can reduce these limitations and improve 
the quality of evidence of the effects of synbiotic supplementation on NAFLD.   
 
Conclusion: Randomized controlled trials studying synbiotics as a treatment for NAFLD 
provide evidence to support their use as an adjunctive treatment to nutritional counseling 
and weight loss. Synbiotics are a safe and effective adjunctive treatment for all patients 
with NAFLD.  
 
Keywords: Nonalcoholic fatty liver disease, synbiotics 
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Synbiotic Supplementation as a Treatment for 
Nonalcoholic Fatty Liver Disease 
 
BACKGROUND 
Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic 
liver diseases worldwide.1-4 It is the most common chronic liver disease in the Western 
world.1,4 NAFLD can be subdivided into nonalcoholic fatty liver (NAFL) and 
nonalcoholic steatohepatitis (NASH); NAFL describes when there is hepatic steatosis, or 
accumulation of fat in the liver, but no evidence of significant inflammation, and NASH 
describes hepatic steatosis that does have evidence of hepatic inflammation.5 Thus, when 
a person has NAFLD, they have fat accumulation in the liver with or without 
inflammation of the liver. Other terms that have been used to describe NASH include 
pseudoalcoholic hepatitis, alcohol-like hepatitis, fatty liver hepatitis, steatonecrosis, and 
diabetic hepatitis.1,2 
 One of the major risk factors for NAFLD is central obesity, though lean people 
can be affected by NAFLD as well. Other risk factors include metabolic syndrome, 
diabetes mellitus type 2, and dyslipidemia.6,7 Patients are most often diagnosed with 
NAFLD in their 40s or 50s, and studies are inconclusive in regard to the predilection of 
NAFLD in men or women.8 The diagnosis has three requirements: hepatic steatosis 
shown on imaging or biopsy, exclusion of other causes of hepatic steatosis such as viral 
or autoimmune hepatitis, and exclusion of significant alcohol consumption.9 These 
patients may complain of pain in the right upper quadrant, fatigue, or malaise, though it is 
more likely that they will be asymptomatic.10 The diagnosis could be investigated further 
due to incidental lab findings such as elevated liver enzymes or hepatic steatosis found 
incidentally on abdominal imaging.1 However, it is important to note that elevated liver 
enzymes is not a requirement for the diagnosis, and they are in fact usually normal or 
only minimally elevated. 
 It is important to reduce risk factors and treat NAFLD because it can progress to 
cirrhosis and other complications including hepatocellular carcinoma. Weight loss and 
lifestyle modification are the only generally recommended forms of treatment for 
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NAFLD; pharmacologic agents have been studied, though none of them are yet 
recommended specifically for the treatment of hepatic steatosis.9-13 This is due to the fact 
that most of the trials have been too short and/or the results have conflicted.  
Synbiotics were proposed as a form of treatment due to the anti-inflammatory 
properties of probiotics, and the concept of gut microbiota involvement in the 
pathogenesis of liver disorders.10-13 Synbiotics are formulas containing a combination of 
prebiotics and probiotics, which can have beneficial effects on various disease processes. 
They are a safe, simple, and inexpensive treatment option; side effects are rare, and the 
over-the-counter cost of synbiotics in the United States ranges between $15-$50 
depending on the brand and the number of capsules or amount of powder in the container. 
This systemic review provides evidence that synbiotics are a safe and effective adjunctive 
treatment for nonalcoholic fatty liver disease.  
METHODS 
An exhaustive search of the available medical literature was performed using 
MEDLINE-Ovid, Web of Science, and CINAHL. Search terms included “Non-alcoholic 
fatty liver disease” and “synbiotics.” 
The inclusion criteria were randomized controlled trials with adult humans with 
NAFLD, written in English. Animal studies and studies written in other languages were 
excluded. These eligible articles were assessed using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE) criteria.14 
RESULTS 
The search on MEDLINE-Ovid yielded 10 results, 2 of which were duplicates. 
Web of science gave 5 results, and CINAHL gave 1 result. Of those results, 3 of them 
were randomized controlled trials that fit the inclusion criteria for this review. (See Table 
1). Two of the articles were written 3 years apart by some of the same authors; the Mofidi 
et al study11 refers to their previous study (by Eslamparast et al12) on the use of synbiotic 
supplementation in overweight and obese patients with NAFLD, so the next study11 was 
done similarly with lean patients. The third study by Ferolla et al13 had no requirements 
for BMI.  
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Mofidi et al (2017) 
Fifty lean patients were recruited for the study,11 and were randomly assigned to 
receive either a synbiotic capsule or placebo capsule. Patients were included if they were 
18 years or older, had evidence of hepatic steatosis on the FibroScan (transient 
elastography) with a CAP score of >260, did not have a history of alcohol consumption, 
had a normal or low BMI of <25, had ALT and AST concentrations >1.5 times the upper 
normal range, and had no evidence of any other liver disorders (ie, hepatitis B and C), 
biliary disease, autoimmune diseases, cancer, or inherited disorders affecting the liver. 
They were excluded if they were pregnant or breastfeeding, taking antibiotics or 
hepatotoxic medications at any point during the study, or if they lost >10% body weight 
during the study period.11 
Both groups were encouraged to lead a healthy lifestyle and were advised to 
follow an energy-balanced diet. They were also given the same physical activity 
recommendations. Forty-two of the patients completed all 28 weeks of treatment, but all 
50 were included in the analysis. The primary outcome was reduction of hepatic steatosis, 
as measured by CAP scores of the FibroScan (transient elastography) test. Steatosis was 
reduced in both groups (Table 2), though the reduction in the synbiotic group was 
significantly greater.11  
Secondary outcomes included hepatic fibrosis, hepatic enzymes, lipid profile, and 
inflammatory markers. Similar to the reduction of steatosis, fibrosis was reduced in both 
groups but significantly greater in the synbiotic group. (See Table 2). No significant 
differences were observed between the synbiotic and placebo groups in reduction of 
hepatic enzymes, with the exception of aspartate aminotransferase (AST); both groups 
showed an improvement in serum enzyme levels, but the synbiotic group had a 
significant difference in AST improvement compared to the placebo group. (See Table 
2). Also of note, the synbiotic group also demonstrated a significant difference in the 
improvement of fasting blood sugar (FBS) and triglycerides (TAG).11 
Various organizations helped with the production of this randomized, double-
blind, placebo-controlled clinical trial. Members of the same organizations helped 
develop a similar trial 3 years prior, which will be discussed next.  
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Eslamparast et al (2014) 
 Fifty-two overweight or obese patients were enrolled in this study12 and were 
randomly assigned to receive either a synbiotic capsule or a placebo capsule. The 
synbiotic contained 7 strains of bacteria (Lactobacillus casei, Lactobacillus rhamnosus, 
Streptococcus thermophilus, Bifidobacterium breve, Lactobacillus acidophilus, 
Bifidobacterium longum, and Lactobacillus bulgaricus) and prebiotic 
(fructooligosaccharide) and probiotic cultures and a vegetable capsule; the same strains 
and prebiotic were used in the study by Mofidi et al.11,12  
Patients were included if they were given the diagnosis of NAFLD based on the 
presence of hepatic fibrosis on ultrasound and transient elastography, persistently 
elevated liver enzymes, and they were 18 years or older. They were excluded if they had 
viral hepatitis, alcohol use, other causes of chronic liver disease, diabetes mellitus, 
untreated hypothyroidism, systemic disease, pregnancy, lactation, or lack of effective 
birth control if the women were of childbearing age.12 
Both groups were encouraged to follow an energy-balanced diet and were given 
exercise recommendations. Forty-six patients completed all 28 weeks of treatment, but all 
52 were included in the analysis. The primary outcome of this study was a reduction of 
ALT concentration, which was significant in both the synbiotic group and the placebo 
group. However, the mean reduction of ALT was significantly greater in the synbiotic 
group.12 (See Table 2). 
Secondary outcomes that were measured included the FibroScan (transient 
elastography) score for which they evaluated hepatic fibrosis, inflammatory factor 
concentrations, fasting blood sugar (FBS), and serum aspartate aminotransferase (AST), 
γ-glutamyltransferase (GGT), and alkaline phosphatase (ALP). Patients taking the 
synbiotic demonstrated a significant difference in the reduction of hepatic fibrosis 
compared to the placebo group. The synbiotic group also showed a significant difference 
in the reduction of AST and GGT. Both groups had a significant reduction of FBS. There 
was no significant different between the 2 groups in reduction of ALP. Additionally, the 
inflammatory factor concentrations decreased at the end of the 28 weeks in both groups, 
but again the mean decrease in the synbiotic group was greater.12 (See Table 2).  
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Ferolla et al (2016) 
 Fifty patients were included in this trial13 and were randomly assigned to the 
treatment group, which received a synbiotic and nutritional counseling, or the control 
group, which was only given nutritional counseling. The synbiotic consisted of 
Lactobacillus reuteri with guar gum and inulin.13  
Patients were included if they had a diagnosis of NASH that was confirmed by 
previous liver biopsy, and other causes of liver disease were excluded. They were 
excluded if they consumed >20 grams of alcohol per day (males) or >10 grams of alcohol 
per day (females). Other exclusion criteria included viral hepatitis infections, auto-
immune hepatic disorders, Wilson disease, hemochromatosis and alpha-1-antitripsin 
deficiency, use of steatogenic medications within the past 6 months, exposure to 
hepatotoxins, history of bariatric surgery, contraindication to MRI, and evidence of 
decompensated liver disease.13 
The primary outcome of the study was significant reduction of hepatic steatosis. 
Steatosis was assessed at baseline and at the end of the 12-week study period using MRI-
derived proton density fat fraction (PDFF). The synbiotic group demonstrated a 
significant reduction in steatosis (p=0.027) compared with the control group (p=0.148).13 
(See Table 2).  
Hepatic fibrosis was a secondary outcome and was measured using elastography. 
No significant difference in reduction of fibrosis was observed between the treatment and 
the control groups. Other secondary outcomes included the reduction of ALT, AST, 
GGT, and ALP. Unlike the previous 2 studies reviewed, there was no significant 
reduction of any of these liver enzymes.13 (See Table 2).  
 
DISCUSSION 
NAFLD is a widespread disease, and with the exception of lifestyle 
modifications, there is little known about how to treat it. After integrating the data from 
the 3 studies11-13 reviewed here, it is clear that synbiotics have some utility in treating 
nonalcoholic fatty liver disease as they appear to be effective, inexpensive, and harmless. 
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None of the patients in any of the studies complained of any serious side effects from the 
synbiotics, and only 2 minor side effects were reported in the Eslamparast et al study, 12 
which were moderate headaches and abdominal pain. These side effects resolved without 
recurrence. Moreover, clinicians can consider recommending synbiotics to patients 
regardless of weight, as 2 of the studies12,13 involved overweight or obese patients, while 
the other study11 involved patients with a normal or low BMI. 
The studies by Mofidi et al11 and Eslamparast et al12 were both randomized, 
double-blind, placebo-controlled clinical trials. The study by Ferolla et al13 was a 
randomized controlled trial, though the extent to which it was blinded is uncertain, and 
there was no placebo used. The most serious limitation was in the Ferolla et al study; the 
control group did not receive a placebo pill, but instead was only given nutritional 
counseling. However, the measurements of the various outcomes are standardized, 
objective measurements, which strengthens the study. Additionally, it is stated in the 
Mofidi et al11 and Eslamparast et al12 studies that none of the participants had received 
treatment yet for their diagnosis of NAFLD. It is unclear if this was the case in the 
Ferolla et al.13 This could be viewed as a limitation as well.  
A quality assessment was performed on the outcomes reviewed here, using the 
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
criteria shown in Table 1. The criteria deemed the Mofidi et al11 and Eslamparast et al12 
studies high quality and the Ferolla et al13 study moderate quality. Thus, the overall 
quality of evidence is high. Specifically, reduction of hepatic fibrosis demonstrates high 
quality of evidence, though it did have one inconsistency; the Ferolla et al study13 did not 
find a significant reduction of hepatic fibrosis while the other 2 studies did. However, the 
Ferolla et al study13 was 16 weeks shorter in duration than the other 2 studies.11,12 
Additionally, the Mofidi et al study11 used elastography to measure steatosis, while the 
Ferolla et al study13 used MRI PDFF. The Eslamparast et al study12 used elastography to 
measure fibrosis but did not mention a value for measuring steatosis.  
Further randomized controlled trials should be done using the same synbiotic 
capsules, the same duration, and similar diet and exercise recommendations. It is 
important to have multiple studies with the same controlled variables in order to obtain 
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more accurate results. However, there is nearly no risk of harm in taking synbiotics. 
Thus, due to the low cost and the few side effects in addition to the positive effects shown 
in the studies11-13 reviewed here, it seems as though synbiotics should be a regular part of 
the treatment regimen for all patients with nonalcoholic fatty liver disease.  
 
CONCLUSION 
All three studies concluded that synbiotic supplementation in addition to lifestyle 
modification is superior to lifestyle modification alone in the treatment of NAFLD. Two 
of the studies involved overweight/obese patients, while the other study involved patients 
with a normal or low BMI. This is important given that the majority of patients with 
NAFLD will be overweight; however, it is not limited to overweight patients. The fact 
that the studies found improvement among overweight and non-overweight patients 
strengthens the results. No serious adverse effects were observed, and all 3 randomized 
controlled trials showed some form of improvement in patients with NAFLD. All of this 
information provides strong enough evidence for clinicians to begin giving synbiotics as 
an adjunctive treatment for nonalcoholic fatty liver disease.  
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Table 1: Quality Assessment of Reviewed Articles 
Study Study 
Design 
Downgrade Criteria Upgrade 
Criteria 
 Quality 
Limitations Indirectness Inconsistency Imprecision Publication bias 
Mofidi et al11 RCT Not Serious Not Serious Not Serious Not Serious  Unlikely None High 
Eslamparast et 
al12 
RCT Not Serious Not Serious Not Serious Not Serious  Unlikely None High 
Ferolla et al13 RCT Not Seriousa Not Serious Seriousb Not Serious  Unlikely None Moderate 
a Blinding is uncertain in the Ferolla et al study but no downgrade was applied due to objectivity of outcomes. 
  b The Ferolla et al study did not show a significant difference in reduction of liver fibrosis and didn’t declare whether or not patients were treatment 
naive. 
  RCT = randomized controlled trial 
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Table 2. Summary of Findings 
Outcome 
Mofidi et al11  
mean change from baseline (SE) 
Eslamparast et al12 
mean change from baseline (95% CIs) 
Ferolla et al13 
reduction of median value from baseline to post treatment (95% CIs) 
Synbiotic 
group 
Placebo 
group 
Synbiotic group Placebo group Synbiotic group Placebo group 
Fibrosis -1.71 (0.25) via 
FibroScan in kPa 
-0.71 (0.18) via 
FibroScan in kPa 
9.36 + 1.9 to 6.38 + 1.5 
via elastography* 
7.92 + 2.1 to 7.16 + 2.0 
via elastography* 
3.41  
(2.46; 7.59) via elastography 
3.05 
(2.31; 8.74) via elastography 
Steatosis -59.85 (6.14) -14.14 (1.04) -- -- 14.9 (2.9; 27.4) to 11.5 (4.4–
21.8) 
 via MRI PDFF** 
6.4 (3.9; 23.4) to 7.3 (3.9–
31.1) 
 via MRI PDFF** 
ALT - IU/l -11.61 (0.63) -5.04 (0.13) -25.1  
(-26.2, -24.0) 
-7.3  
(-9.5, -5.1) 
0.9 (0.3; 5.5) to 0.8 (0.2; 4.5) 
—x ref. value 
0.9 (0.4; 3.1) to 1.0 (0.4; 4.4) 
—x ref. value 
AST - IU/l -10.8 (0.50) -1.98 (0.09) -31.3  
(-32.1, -30.5) 
-7.9  
(-11.1, -4.8) 
0.9 (0.4; 3.8) to 0.9 (0.3; 4.1)  
—x ref. value 
0.9 (0.5; 3.7) to 0.9 (0.3; 4.3) 
—x ref. value 
GGT - IU/l -28.65 (1.88) -3.20 (0.22) -15.08  
(-15.5, -14.7)  
-5.21  
(-6.6, -3.9) 
1.6 (0.5; 17.1) to 1.7 (0.6; 9.4)  
—x ref. value 
1.8 (0.3; 21.7) to 1.5 (0.5; 
12.1) —x ref. value 
FBS - mg/dl -17.33 (4.98)  -2.47 (0.52) -7.96 
(no CIs given) 
-2.82 
(no CIs given) 
99.0 (80; 293) to 101.0 (83; 322) 109 (85; 280) to 127 (84; 326) 
Insulin - mU/l 0.26 (0.78)  -0.38 (0.14) -2.02 
(no CIs given) 
-0.92 
(no CIs given) 
-- -- 
HOMA-IR -0.10 (0.22)  -1.32 (0.03) -0.68  
(-0.8, -0.5)  
-0.39  
(-0.5, -0.3) 
-- -- 
QUICKI 0.02 (0.01)  0.07 (0.00) -- -- -- -- 
TAG - mg/dl -32.23 (10.04)  -9.80 (2.35) -- -- 176 (100; 328) to 173 (81; 572) 147 (69–610) to 183 (66.4; 
663) 
HDL - mg/dl 3.69 (1.64) 0.95 (0.75) -- -- 44.9 + 10.3 to 44.3 + 8.9 46.7 + 11.7 to 46.2 + 10.5 
LDL - mg/dl -24.85 (11.71)  -13.42 (2.39) -- -- 125.2 + 28.0 to 125.8 + 35.5 109.3 + 32.7 to 104.2 + 24.8 
Total C - mg/dl -46.09 (12.04)  -16.00 (4.67) -- -- 205.4 + 34.6 to 208.9 + 38.4 190.9 + 42.5 to 195.5 + 30.4 
hs-CRP - ng/ml -1162.61 
(437.65)  
-426.57 
(132.41) 
-2.30  
(-3.0, -1.5)  
-1.04  
(-1.5, -0.6) 
-- -- 
TNF-α - pg/ml -1.22 (0.82) -0.30 (0.22) -1.40  
(-1.7, -1.1)  
-0.59  
(-0.8, -0.3) 
-- -- 
NF-κB p65 -0.01 (0.00)  -0.01 (0.00) -0.016  
(-0.022, -0.011)  
0.001  
(-0.004, -0.007) 
-- -- 
P values <0.05; P values < 0.0001  
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*In the synbiotic group, 95% of patients showed some improvement in their fibrosis score, whereas the scores of 5% remained unchanged. Of those with improvements, 8% had 
a 1-level reduction in their fibrosis score, whereas 36% and 56% had 2- and 3-level reductions, respectively. Fibrosis scores also decreased in the placebo group, but less than in 
the synbiotic group. Only 36% of the patients in this group had one or more levels of reduction in their fibrosis scores.2 
**In line with this result, 40.7% of the patients in the study group were classified as having moderate/severe steatosis (grades 2–3) in MRI at baseline; and, after the synbiotic 
supplementation, this proportion fell to 18.5% (p = 0.031). Therefore, the proportion of patients initially with mild steatosis (grades 0–1) increased from 59.2% to 81.5% (p = 
0.031). In the control group, they did not observe improvement in the grade of steatosis (p = 1.00).3 
 
Abbreviations: CIs, confidence intervals; MRI: magnetic resonance imaging; PDFF: hepatic proton density fat fraction; kPa: kiloPascal; NAFLD: nonalcoholic fatty liver disease; 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transpeptidase; FBS, fasting blood sugar; HOMA-IR, homeostatic model assessment of insulin 
resistance; QUICKI, quantitative insulin sensitivity check index; C, cholesterol; hs-CRP, high-sensitive C-reactive protein. 
 
